MedTrace Logo

A Study of Remimazolam Tosilate for Sedation in Non-intubated Diagnostic and Therapeutic Procedures

NCT06216444 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2024-01-22

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of Remimazolam Tosilate for Injection for sedation in non-intubated diagnostic and therapeutic procedures

Conditions

  • Sedation in Non-intubated Diagnostic and Therapeutic Procedures

Interventions

DRUG

Remimazolam Tosilate for Injection

Initial loading dose of 5mg, with additional doses of 2.5mg as necessary

DRUG

Remimazolam Tosilate for Injection

Initial loading dose of 10mg, with additional doses of 2.5mg as necessary

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-31
Primary Completion
2024-03-31
Completion
2024-03-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06216444 on ClinicalTrials.gov